Jeff is a drug discovery scientist who is an innovative expert in assay development and compound screening. His experience ranges from molecular pharmacology to preclinical development in diabetes and other metabolic diseases. He has served as scientific lead in collaborations with multiple pharma companies and CROs to implement novel biochemical and cell-based assays and screening paradigms to successfully advance compounds with novel mechanisms of action. While at Metabolex (now CymaBay) he led projects that uncovered new approaches to metabolic disease via improvement of pancreatic islet health. One of these projects spanned from target discovery to clinical studies. At Reset Therapeutics, Jeff helped define the critical role of circadian regulation (and dysregulation) in metabolic disease and worked with an integrated team to define the potential of molecular clock targeted therapeutics. Jeff received a Ph.D. from the University of Texas Health Science Center at Houston and was a postdoctoral scholar at UCSF in the Hormone Research Institute.